Foley Partner Courtenay Brinckerhoff was quoted in an article that appeared in the August 2011 issue of Nature Biotechnology titled “US Court Bolsters Biotech Patent Protection.” Brinckerhoff discusses the outcome of Therasense vs. Becton Dickinson & Company and its significance to biotech companies. She observes that the decision offers patent holders a new basis for defeating an inequitable conduct charge, but adds that litigants are likely to continue raising the defense in order to render an entire patent unenforceable until more court decisions have rejected weaker charges of inequitable conduct.
People
Related News
August 13, 2025
In the News
Leigh Riley on Elevating Partner Development with Foley's PEAK Program – 'We can't stop learning'
Foley & Lardner LLP partner Leigh Riley appeared on the Big Law Life podcast to share how Foley is redefining professional development to meet the needs of the firm's partners and the demands of modern legal practice.
August 8, 2025
In the News
Gregory Husisian and David Simon Uncover the High Stakes of Tariff Evasion
Foley & Lardner LLP partners Gregory Husisian and David Simon are featured for their insights on how the U.S. government is cracking down on tariff evaders in the Newsweek article, "America Is Making Billions From Catching 'Tariff Cheaters.'"
August 7, 2025
In the News
Kyle Faget Weighs in on Trump Pharma Tariffs
Foley & Lardner LLP partner Kyle Faget assessed the Trump administration's implementation of import tariffs on the pharmaceutical industry in the Pharma Life Sciences article, "Trump's pharma import tariffs threaten drug pricing, generics."